Notice to convene AGM
Mar 3, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that the Orphazyme A/S Annual General Meeting will be held on.
Appendix 2 revised remuneration policy
Appendix 1 candidates for the board of directors
Read moreMajor shareholder announcement
Mar 2, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Danske Bank A/S that Danske Bank as of February 27, 2020 holds a total 1,244,908 shares in the Company, corresponding to 4.60% of the share capital and that Danske Bank as of February 27, 2020 controls 6.72% of the voting rights in the Company.
Major shareholder announcement
Read moreOrphazyme announces Annual Report 2019
Feb 28, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces its Annual Report for the period January 1–December 31, 2019.
Orphazyme announces annual report 2019
Read moreOrphazyme to present at Cowen & Company 40th Annual Health Care Conference
Feb 27, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that Kim Stratton, Chief Executive Officer at Orphazyme, will present at the Cowen & Company 40th Annual Health Care Conference taking place March 2-4, 2020, in Boston, United States.
Orphazyme to present at cowen company 40th annual ...
Read moreOrphazyme Annual Report 2019 Presentation
Feb 20, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that the Company will be hosting an investor call at which Chief Executive Officer, Kim Stratton, and Chief Financial Officer, Anders Vadsholt, will be presenting the Orphazyme Annual Report 2019. The presentation will be followed by a Q&A session.
Orphazyme annual report 2019 presentation
Read moreMajor shareholder announcement
Feb 13, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Danske Bank A/S that Danske Bank as of February 12, 2020 holds a total 1,161,561 shares in the Company, corresponding to 4.85% of the share capital and that Danske Bank as of February 12, 2020 controls 7.24% of the voting rights in the Company.
Major shareholder announcement
Read moreMajor shareholder announcement
Feb 12, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Consonance Capman GP LLC that as of February 11, 2020, Consonance Capman GP LLC indirectly holds 1,900,000 shares and voting rights in Orphazyme, corresponding to 7.03% of the total share capital and voting rights of Orphazyme.
Major shareholder announcement
Read moreOrphazyme announces presentations at WORLDSymposium™
Feb 11, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces two presentations at the 16th Annual WORLDSymposium™, Orlando, Florida, February 10-13, 2020. These presentations highlight data from the Company’s randomized double-blind, placebo-controlled phase 2/3 trial with investigational drug candidate, arimoclomol, in Niemann-Pick disease Type C (NPC), and include previously reported primary endpoint data, pre-specified and post-hoc subgroup analyses, safety, and supportive biomarker data.
Orphazyme announces presentations at worldsymposium
Read moreReporting of transactions in Orphazyme’s shares
Feb 11, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby notifies receipt of the attached information of transactions in Orphazyme’s shares by a person closely associated with a person discharging managerial responsibilities in Orphazyme pursuant to Article 19 of the Market Abuse Regulation.
Notification orpha pooling person closely associated ...
Transactions in Orphazymes shares
Read moreMajor shareholder announcement
Feb 11, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby notifies receipt of the attached major shareholder notifications pursuant to Section 30 of the Danish Capital Markets Act.
Major shareholder letter to Orphazyme as novo holdings ...
Major shareholder letter to Orphazyme
Major shareholder announcement
Read more